For the quarter ending 2026-03-31, KAPA has $5,744K in assets. $3,675K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 3,675 | 4,491 | 5,575 | 3,034 |
| Vendor advances, gross | 1,756 | 3,271 | 3,271 | - |
| Less accumulated amortization | 1,131 | 2,426 | 2,214 | - |
| Vendor advances, net | 625 | 845 | 1,057 | 1,717 |
| Prepaid expenses and other current assets | 143 | 51 | 24 | 88 |
| Total current assets | 4,443 | 5,387 | 6,656 | 4,839 |
| Deferred offering costs | 1,279 | 1,091 | 1,308 | 1,692 |
| Intangible assets, net | 22 | 62 | 102 | 142 |
| Total other assets | 1,301 | 1,153 | 1,410 | 1,834 |
| Total assets | 5,744 | 6,540 | 8,066 | 6,673 |
| Accounts payable and accrued expenses | 431 | 199 | 402 | 676 |
| Total current liabilities | 431 | 199 | 402 | 676 |
| Common stock, par value 0.001, 100,000,000 shares authorized 21,411,198 and 20,821,353 shares issued and outstanding, respectively | 21 | 21 | 21 | 18 |
| Additional paid-in capital | 21,208 | 20,582 | 20,540 | 17,478 |
| Accumulated deficit | -15,916 | -14,262 | -12,897 | -11,499 |
| Total shareholders equity | 5,313 | 6,341 | 7,664 | 5,997 |
| Total liabilities and shareholders equity | 5,744 | 6,540 | 8,066 | 6,673 |
Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD. (KAPA)